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Abstract:  To  obtain  structurally  novel  and  bioactive  natural  compounds  from  
marine-derived  microorganisms,  the  effect  of  high  salt  stress  on  secondary  metabolite 
production in the marine-derived fungal strain, Spicaria elegans KLA-03, was investigated. 
The organism, which was isolated from marine sediment, produced different secondary 
metabolites  when  cultured  in  3%  and  10%  saline  conditions.  Four  characteristic 
metabolites, only produced in the 10% salinity culture, were isolated, and their structures 
were  identified  as  (2E,2'Z)-3,3'-(6,6'-dihydroxybiphenyl-3,3'-diyl)diacrylic  acid  (1), 
aspulvinone E (2), aspochalasin E (3) and trichodermamide B (6), according to their 1D 
and 2D NMR spectra. Compound 1 is a new compound. High salt stress may therefore be a 
promising  means  to  induce  the  production  of  new  and  chlorinated  compounds  in 
halotolerant  fungi.  Compound  1  showed  moderate  antibacterial  activity  against 
Pseudomonas  aeruginosa  and  Escherichia  coli  with  minimum  inhibitory  concentration 
(MIC) values of 0.038 and 0.767 mM, respectively.  
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1. Introduction  
The marine environment is an important source of halotolerant microorganisms. During our studies 
of halotolerant “talented strains” [1], we have previously reported that the marine-derived fungal strain, 
Spicaria  elegans  KLA-03,  produces  many  interesting,  bioactive  compounds  in  different  media 
containing 3% salt [2–4]. In the course of our ongoing investigations of structurally new and bioactive 
compounds from halotolerant fungi in hypersaline media [5–9], and to investigate whether high salt 
stress  could  induce S.  elegans KLA-03 to  produce new compounds, the secondary  metabolites of 
S. elegans KLA-03, which had been cultivated under conditions of 10% salinity, were studied. As a 
result, a new metabolite, (2E,2'Z)-3,3'-(6,6'-dihydroxybiphenyl-3,3'-diyl) diacrylic acid (1), together 
with five known compounds, aspulvinone E (2) [10], aspochalasin E (3) [11], aspergillazine A (4) [2], 
and trichodermamides A (5) [2] and B (6) [12] were isolated and identified. Compounds 1–3 and 6 
were not produced by S. elegans KLA-03 when cultivated in a low-salt (3%) medium [2–4]. 
2. Results and Discussion  
2.1. Identification of Metabolites from S. Elegans in 10% Saline Conditions 
Fungus S. elegans KLA-03 was incubated in a high-salt medium containing 10% artificial sea salt 
and extracted with EtOAc to afford a crude extract. The crude extract (4 g) was separated by extensive 
chromatography  using silica gel,  Sephadex  LH-20 and HPLC to  give compounds  1–6 (Figure  1). 
Compound 1 was isolated as a white powder. Its molecular formula was established as C18H14O6 by 
HRESIMS at m/z 325.0716 [M − H]
− (calculated for C18H13O6, 325.0712). The IR spectrum showed 
the presence of hydroxy groups (3430, 3215 cm
−1), a conjugated carbonyl group (1677 cm
−1), double 
bond (1617 cm
−1) and benzene ring (1499 cm
−1). The UV absorption at λmax 300 nm indicated that a 
conjugated system was present in 1. Two sets of coupled 
1H NMR signals at δH: 7.64 (dd, J = 8.7,  
2.3 Hz), 7.57 (d, J = 2.3 Hz), 6.87 (d, J = 8.7 Hz) and 7.52 (dd, J = 8.7, 2.3 Hz), 7.40 (d, J = 2.3 Hz),  
6.91 (d, J = 8.7 Hz) revealed the presence of two 1,3,4-trisubstituted aromatic fragments. Another two 
sets  of  coupled  proton  signals  at  δH:  7.52  (d,  J  =  15.6  Hz),  6.29  (d,  J  =  15.6  Hz)  and  6.80  (d,  
J = 12.8 Hz), 5.74 (d, J = 12.8 Hz) suggested the presence of two 1,2-disubstituted double bonds with 
E-  and  Z-configurations,  respectively.  Four  exchangeable  proton  signals  at  δH  12.22  (2H)  and  
9.82 (2H) were also observed by 
1H NMR. The DEPT 
13C NMR spectrum exhibited 18 signals, and 
indicated the presence of two 3,4-disubstituted phenylpropenoic acid moieties. This assignment was 
supported by HMBC correlations from H-7 to C-9 and C-4, from H-7′ to C-9′, and C-4′, from H-8 to 
C-3, and from H-8’ to C-3′ (Table 1). Key HMBC correlations between H-2 and C-1′, and H-2′ and  
C-1, revealed that the two phenylpropenoic acid moieties were connected via a C3−C3′ single bond 
(Figure  1).  Thus,  compound  1  was  determined  to  be  (2E,2'Z)-3,3'-(6,6'-dihydroxybiphenyl-3,3'-
diyl)diacrylic acid. Mar. Drugs 2011, 9                        
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Figure 1. Structures of metabolites 1–6 produced by S. elegans when cultured in 10% 
saline conditions, and key COSY and HMBC correlations used to assign the structure of 
the new compound 1. 
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Table 1. Antimicrobial activities of compounds 1–6 (“−” indicates not measured). 
Compound  
MIC (mM) 
Enterobacter 
aerogenes 
Escherichia 
coli 
Pseudomonas 
aeruginosa 
Staphylococcus 
aureus 
Candida 
albicans 
1  0.153  0.038  0.767  1.534  0.383 
2  0.084  0.338  3.378  3.378  0.844 
3  0.059  0.239  1.193  2.387  0.298 
4  0.029  0.231  0.231  0.231  0.289 
5  0.056  0.223  2.227  0.223  0.557 
6  0.056  0.222  0.222  0.222  0.278 
Ciprofloxacin 
lactate 
0.001  0.004  0.030  0.001  − 
Ketoconazole  −  −  −  −  0.005 
2.2. Effect of Salt Stress on Secondary Metabolite Production 
Little has been published in the literature on the metabolites produced by the fungus S. elegans, 
with  most  reports  originating  from  our  lab.  A  series  of  compounds,  mainly  cytochalasins  and 
aspochalasins  with  antitumor  activities,  were  isolated  and  identified  from  the  cultivation  of  this 
organism  at  3%  salinity  [2–4,13,14].  It  has  been  reported  that  halotolerant  fungi  have  special 
osmoregulatory mechanisms to regulate intracellular osmotic potential, which allows them to survive 
under a variety of saline conditions, including high salt conditions [15]. The secondary metabolites 
produced  by  the  organism  may  be  regulated  by  environmental  factors  such  as  salinity  [16].  To 
investigate whether high salt stress could activate silent genes encoding secondary metabolites in S. 
elegans KLA-03, the organism was fermented at 3% and 10% salinity and the metabolites produced Mar. Drugs 2011, 9                        
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were monitored by HPLC. When cultured at 10% salinity, S. elegans KLA-03 was found to produce 
different compounds to those observed when it was cultured at 3% salinity (Figure 2).  
Figure 2. HPLC profiles of secondary metabolites from S. elegans KLA-03 at 3% and 10% 
salinity (gradient elution: 0–5 min, 5% MeOH; 5–50 min, 5%–100% MeOH; 50–60 min, 
100% MeOH; 60–65 min, 100%–5% MeOH). 
 
The  main  products  observed  under  low  salinity  culture  conditions,  cytochalasins  
(tR 37–45 min) [8,9], were present at significantly lower levels when the organism was cultured under 
high salinity conditions. In contrast, the levels of other metabolites (tR 28–35 min) were significantly 
higher in the high salinity culture. High salinity conditions therefore induced the fungus S. elegans 
KLA-03 to produce much more polar metabolites. Extraction and HPLC-guided purification resulted 
in the isolation and identification of one new compound (1) and five known compounds (2–6), of 
which compounds 4 and 5 had previously been identified from the fermentation broth of this strain 
using 3% salinity conditions [2]. The biosynthetic pathways expressed by S. elegans KLA-03 under 
high salinity conditions are therefore different from those expressed under low salinity conditions. 
Chlorinated metabolite 6 was not produced at 3% salinity, suggesting that a halogenase enzyme may 
be activated under high salt conditions, and that the high concentration of chloride was exploited by 
S. elegans  KLA-03  to  synthesize  chlorinated  compounds.  The  mass  of  the  crude  EtOAc  extracts 
obtained under the two conditions were markedly different, with 4 g obtained from a 50 L fermentation 
broth at 10% salinity, while 15 g was obtained from a 15 L 3% saline culture [3,4]. This suggests that 
high salt conditions lead to significantly lower overall metabolite productivity, as well as a change in  
metabolite profile.
   Mar. Drugs 2011, 9                        
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2.3. Antimicrobial Effects of Secondary Metabolites 
The antimicrobial activities of compounds 1–6 against Enterobacter aerogenes, Escherichia coli, 
Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans were evaluated using an agar 
dilution  method  (Table  1)  [17].  New  compound  1  showed  moderate  antibacterial  activity  against 
P. aeruginosa  and  E.  coli.  In  addition,  moderate  antibacterial  activity  against  E.  aerogenes  for 
compounds  2–6,  and  P.  aeruginosa  for  4  and  6  were  also  observed.  The  minimum  inhibitory 
concentrations (MICs) were defined as the lowest concentration at which no microbial growth could  
be observed. 
Aspochalasin E (3) and trichodermamide B (6) have been reported to be cytotoxic to HCT-116 cells, 
with IC50 values of 6.3 and 0.32 μg/mL, respectively [11,12]. Compounds 4 and 5 have been reported 
to display weak cytotoxicity against HL-60 cells, with IC50 values of 84 and 89 μM, respectively [2].  
3. Experimental Section  
3.1. General Experimental Procedures  
UV spectra were recorded on a Beckman DU 640 spectrophotometer. IR spectra were obtained on a 
Nicolet NEXUS 470 spectrophotometer as KBr disks.
 1H, 
13C and DEPT NMR spectra and 2D-NMR 
spectra were recorded on a JEOL JNMECP 600 spectrometer using TMS as an internal standard, and 
chemical shifts were recorded as δ values. ESIMS was measured on a Q-TOF Ultima Global GAA076 
LC mass spectrometer.  Semipreparative HPLC was  performed using an ODS column  (YMC-pack 
ODS-A, 10 ￗ 250 mm, 5 μm, 4 mL/min). Analytical HPLC was performed using an ODS column 
(YMC-pack C18, 4.6 ￗ 250 mm, 5 μm, 2 mL/min). TLC was performed on plates precoated with silica 
gel  GF254  (10–40  μm)  and  column  chromatography  (CC)  was  carried  out  using  silica  gel  
(200–300  mesh,  Qingdao  Marine  Chemical  Factory,  Qingdao,  China)  and  Sephadex  LH-20 
(Amersham  Biosciences,  Sweden).  Artificial  sea  salt  used  in  culture  media  was  purchased  from 
Qingdao Marine Chemical Factory, Qingdao, China. 
3.2. Fungal Material  
The fungus S. elegans KLA-03 was isolated from marine sediments collected in Jiaozhou Bay, 
China. It was identified by Prof. C. X. Fang and preserved in the China Center for Type Culture 
Collection (No. CCTCCM 205049). Working stocks were prepared on potato dextrose agar slants and 
stored at 4 ° C. 
3.3. Fermentation and Extraction  
The same incubation and extraction methods were used for the 10% artificial sea salt culture as 
those used previously for culturing with 3% sea salt [8]. In brief, the fungus S. elegans KLA-03 was 
grown under static conditions at 25  ° C for 25 days in 180 1 L conical flasks containing a liquid 
medium (300 mL/flask) composed of glucose (20 g/L), peptone (5 g/L), malt extract (3 g/L), yeast 
extract (3 g/L), artificial sea salt (10 g/L) and tap water, after adjusting the pH of the media to 7.0. The 
fermented whole broth (54 L) was filtered through cheesecloth to separate the supernatant from the Mar. Drugs 2011, 9                        
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mycelia. The supernatant was concentrated under reduced pressure to about 5 L and then extracted 
three times with EtOAc to give an EtOAc extract, while the mycelia were extracted three times with 
acetone. The acetone was removed under reduced pressure to afford a residual aqueous solution. This 
aqueous solution was extracted three times with EtOAc to give a further EtOAc crude extract. The 
EtOAc  solutions  were  then  combined  and  concentrated  under  reduced  pressure  to  give  a  final  
crude extract (4.0 g).  
3.4. Purification  
The  extract  (4.0  g)  from  S.  elegans  cultured  in  10%  saline  medium  was  separated  into  three 
fractions on a silica gel column using a step gradient elution of CHCl3–MeOH. Fraction 3 was further 
purified by chromatography on  an ODS  column, eluted using  gradient  elution  of MeOH–H2O, to 
provide  three  fractions.  The  sixth  fraction  obtained  from  this  purification  step  (Fraction  3-6)  was 
further  separated  on  a  silica  gel  column  to  provide  compound  4  (15.3  mg),  and  13  subfractions. 
Fractions 3-6-9 and 3-6-13 were initially purified using Sephadex LH-20 (CHCl3:MeOH, 1:1) and 
further purified using semipreparative HPLC to give 1 (3 mg, tR 11.50 min, isocratic elution with 55% 
MeOH) and 5 (5.4 mg, tR10.38 min, 50% MeOH), respectively. Fraction 3-11 was partially purified by 
chromatography on Sephadex LH-20 (CHCl3:MeOH, 1:1) and further purified on a silica gel column 
eluted with a gradient of CHCl3–MeOH to provide five subfractions. Fraction 3-11-2-1 was further 
purified by semipreparative HPLC to give compound 3 (14.2 mg, tR 11.7 min, isocratic elution with 
55% MeOH). Compounds 2 and 6 (2.5 mg, tR 16.15 min, and 9.7 mg, tR 12.78 min, respectively, 
isocratic elution with 55% MeOH) were purified from Fraction 3-11-2-2 by semipreparative HPLC. 
Table 2. 
1H- and 
13C-NMR (600 and 150 MHz) data for 1 in DMSO-d6. 
position  δC  δH (J in Hz)  HMBC (H→C) 
1H-
1H COSY 
1  126.0 s       
2  131.9 d  7.40 (1H, d, 2.3)  1′, 4, 7   
3  125.0 s       
4  128.6 d  7.52 (1H, dd, 8.7, 2.3)  2, 6, 7  5 
5  116.0 d  6.91 (1H, d, 8.7)  1, 3  4 
6  157.2 s       
7  144.3 d  7.52 (1H, d, 15.6)  2, 4, 9  8 
8  115.3 d  6.29 (1H, d, 15.6)  3, 9  7 
9  167.9 s       
1′  124.8 s       
2′  134.2 d  7.57 (1H, d, 2.3)  1, 4′, 7′   
3′  125.5 s       
4′  131.1 d  7.64 (1H, dd, 8.7, 2.3)  2′, 6′, 7′  5′ 
5′  115.1 d  6.87 (1H, d, 8.7)  1′, 3′  4′ 
6′  156.0 s       
7′  141.5 d  6.80 (1H, d, 12.8)  2′, 4′, 9′  8′ 
8′  117.0 d  5.74 (1H, d, 12.8)  3′, 9′  7′ 
9′  167.7 s       Mar. Drugs 2011, 9                        
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(2E,2'Z)-3,3'-(6,6'-Dihydroxybiphenyl-3,3'-diyl)diacrylic  acid  (1):  white  amorphous  powder;  UV 
(MeOH) λmax 300 nm; IR (KBr) νmax 3430, 3215, 1617, 1499 cm
-1; 
1H and 
13C NMR, see Table 2. 
HRESIMS m/z 325.0716 [M − H]
– (calcd 325.0712 for C18H13O6). 
3.5. Bioassays 
Antimicrobial activities against E. aerogenes, E. coli, P. aeruginosa, S. aureus and C. albicans were 
evaluated using an agar dilution method [17]. The tested strains were cultivated in LB agar plates for 
bacteria and in YPD agar plates for C. albicans, at 37 ° C. Compounds 1–6 and positive controls were 
dissolved in 5% DMSO-H2O at different concentrations from 1000 to 62.5 μg/mL and then from 50 to 
0.78 μg/mL, using continuous 2-fold dilution. The test solutions (5 μL) were absorbed onto paper disks 
(5 mm diameter) and placed on the assay plates. After 24 h incubation, zones of inhibition (mm in 
diameter)  were  recorded.  The  minimum  inhibitory  concentrations  were  defined  as  the  lowest 
concentration at which an inhibition zone could be observed.  
4. Conclusions  
In  summary,  four  metabolites,  including  a  new  compound  and  a  chlorinated  compound  with 
antibacterial activity, were identified from the fungus S. elegans KLA-03 grown under high salt stress 
conditions. High salt stress affected the overall quantity of secondary metabolites produced and the 
metabolite profile. This indicates that the regulation of salinity could be a promising way to obtain new 
compounds and chlorinated compounds from halotolerant fungi for drug screening.  
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